| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CAPR Stock Overview
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders.
Capricor Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.89 |
| 52 Week High | US$5.85 |
| 52 Week Low | US$2.56 |
| Beta | 5.03 |
| 1 Month Change | -3.17% |
| 3 Month Change | 55.24% |
| 1 Year Change | 21.64% |
| 3 Year Change | 63.54% |
| 5 Year Change | -52.52% |
| Change since IPO | -88.36% |
Recent News & Updates
Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03
Capricor Therapeutics press release (NASDAQ:CAPR): Q2 GAAP EPS of -$0.29 misses by $0.03. As of June 30, 2022, the Company’s cash, cash equivalents and marketable securities totaled approximately $51.4 million, compared to approximately $34.9 million on December 31, 2021. No shares were sold under the Company’s at-the-market program in the second quarter of 2022. Shares -2.65%.
Shareholder Returns
| CAPR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.9% | 1.4% | 3.6% |
| 1Y | 21.6% | -19.6% | -9.6% |
Return vs Industry: CAPR exceeded the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: CAPR exceeded the US Market which returned -10.2% over the past year.
Price Volatility
| CAPR volatility | |
|---|---|
| CAPR Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 12.6% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CAPR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: CAPR's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 48 | Linda Marbán | https://www.capricor.com |
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19.
Capricor Therapeutics, Inc. Fundamentals Summary
| CAPR fundamental statistics | |
|---|---|
| Market Cap | US$119.05m |
| Earnings (TTM) | -US$25.05m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.8x
P/E RatioIs CAPR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CAPR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$16.61m |
| Gross Profit | -US$16.61m |
| Other Expenses | US$8.44m |
| Earnings | -US$25.05m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.03 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CAPR perform over the long term?
See historical performance and comparison